首页> 美国卫生研究院文献>other >Risk Stratification by Regadenoson Stress Magnetic Resonance Imaging in Patients With Known or Suspected Coronary Artery Disease
【2h】

Risk Stratification by Regadenoson Stress Magnetic Resonance Imaging in Patients With Known or Suspected Coronary Artery Disease

机译:已知或怀疑的冠状动脉疾病患者通过Regadenoson应力磁共振成像进行风险分层

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

The aim of this study was to investigate the association between major adverse cardiovascular events (MACEs) and inducible ischemia on regadenoson cardiac magnetic resonance (CMR) myocardial perfusion imaging (MPI) performed at 3.0 T. Regadenoson stress CMR MPI is increasingly used to assess patients with suspected ischemia; however, its value in patient prognostication and risk reclassification is only emerging. A total of 346 patients with suspected ischemia who were referred for regadenoson CMR were studied. The prognostic association of presence of inducible ischemia by CMR with MACEs was determined. In addition, we assessed the extent of net reclassification improvement by CMR beyond a clinical risk model. There were 52 MACEs during a median follow-up period of 1.9 years. Patients with inducible ischemia were fourfold more likely to experience MACEs (hazard ratio, 4.14, 95% confidence interval 2.37 to 7.24, p <0.0001). In the best overall model, presence of inducible ischemia conferred a 2.6-fold increased hazard for MACEs adjusted to known clinical risk markers (adjusted hazard ratio 2.59, 95% confidence interval 1.30 to 5.18, p = 0.0069). Patients with no inducible ischemia experienced a low rate of cardiac death and myocardial infarction (0.6% per patient-year), whereas those with inducible ischemia had an annual event rate of 3.2%. Net reclassification improvement across risk categories (low <5%, intermediate 5% to 10%, and high >10%) by CMR was 0.29 (95% confidence interval 0.15 to 0.44), and continuous net reclassification improvement was 0.58. In conclusion, in patients with clinical suspicion of myocardial ischemia, regadenoson stress CMR MPI provides robust risk stratification. CMR MPI negative for ischemia was associated with a very low annual rate of hard cardiac events. In addition, CMR MPI provides effective risk reclassification in a substantial proportion of patients.
机译:这项研究的目的是调查主要不良心血管事件(MACE)与可诱导的缺血性之间在3.0 T时进行的瑞格狄森心脏磁共振(CMR)心肌灌注显像(MPI)之间的关联。瑞格狄森应力CMR MPI越来越多地用于评估患者怀疑有局部缺血;然而,其在患者预后和风险重新分类中的价值才刚刚出现。共研究了346例因缺血再灌注疑似缺血的患者,他们接受了regadenoson CMR检查。确定了由CMR与MACE引起的可诱导缺血的预后关联。此外,我们评估了超出临床风险模型的CMR改善的净重分类的程度。在1.9年的中位随访期内有52个MACE。诱发性缺血的患者发生MACE的可能性增加四倍(危险比为4.14,95%置信区间为2.37至7.24,p <0.0001)。在最佳的总体模型中,对于根据已知临床风险指标进行调整的MACE,可诱导缺血的存在使危险增加2.6倍(调整后的风险比2.59,95%置信区间1.30至5.18,p = 0.0069)。没有可诱发性缺血的患者发生心源性死亡和心肌梗塞的几率较低(每患者年0.6%),而具有可诱导性缺血的患者的年事件发生率为3.2%。 CMR对所有风险类别(低<5%,中级5%至10%和高> 10%)的净重分类改进为0.29(95%置信区间0.15至0.44),并且连续净重分类改进为0.58。总之,在临床怀疑有心肌缺血的患者中,regadenoson压力CMR MPI可提供可靠的危险分层。缺血性CMR MPI阴性与硬心事件的年发生率极低有关。此外,CMR MPI在相当一部分患者中提供了有效的风险重新分类。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号